@FiercePharma: Gilead's John Martin replacing Milligan as CEO. Release | Follow @FiercePharma
@EricPFierce: ICYMI from FiercePharmaManufacturing: Novartis is revamping its manufacturing after having disposed of 25 plants. Story | Follow @EricPFierce
@CarlyHFierce: Riding Q4 diabetes growth, Lilly aims for even more with Jardiance. Report | Follow @CarlyHFierce
> Presidential candidate Hillary Clinton continues to demonize Valeant Pharmaceuticals ($VRX) and its drug price hikes, with her campaign posting a video of her in Iowa calling the increases, "predatory" and wrong. Story
> India's Wockhardt has reportedly received an FDA Form 483 for another of its plants. Story
> Sanofi ($SNY) says it has has signed a memorandum of cooperation with Iran in which it will consider expanding partnerships with local manufacturers and transfer technology to Iran. Report
Medical Device News
@FierceMedDev: ICYMI: Investor urges J&J to spin out poor-performing device, consumer businesses. Article | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+. Article | Follow @VarunSaxena2
@EmilyWFierce: ICYMI: J&J to fork over $120M to settle thousands of vaginal mesh suits. Article | Follow @EmilyWFierce
> Vascular Flow Technologies raises $14M+ for its prosthetic vascular graft. Story
> Walgreens severs some ties to Theranos amid CMS lab inspection fallout. Report
Biotech News
@FierceBiotech: ICYMI: Merck gets FDA OK to go toe-to-toe with Gilead's hep C market goliath. Article | Follow @FierceBiotech
@JohnCFierce: Gee, so Allergan does R&D? How surprising. (droll overtone here.) rapastinel/GLYX-13 BTD $AGN. Release | Follow @JohnCFierce
@DamianFierce: this man missed a huge opportunity in orthopedics. More from STAT | Follow @DamianFierce
> Allergan's depression drug bags a 'breakthrough' tag on the way to Phase III. Article
> Replacing a biotech legend, Gilead's new CEO inherits sky-high expectations. Story
> Allergan links with AstraZeneca on new antibiotic treatment. Report